Dr. Varun Bhargava is the Consultant Cardiologist at the CARE Hospitals in Nagpur. With 40 years of experience in the field of Cardiac Sciences, Dr. Varun Bhargava has worked and treated many patients around the world. He gained a scholarship from second MBBS and a Silver Medal in Ophthalmology and General surgery in Final MBBS. He was member Board of studies Modern medicine – Nagpur University for 10 years, and the past President of Cardiological society of India, Nagpur, Dr. Varun Bhargava was the Author of Book – Cardiology Clinical Practice. He is the Managing Director at CARE Hospital ,Nagpur, and was also in the Indian Institute of Management Ahmedabad-Executive Hospital Management Programme ( 2012).
Dr. Varun Bhargava was the director of Nishita – E – Healthcity- Portal for online consultation, and Established Cardiac Cath Lab at Central India Institute of Medical sciences Nagpur. The Prevalence of atrial fibrillation in an urban population in India: the Nagpur pilot study was conducted by him along with another case study on Submitral aneurysmorrhaphy with mitral valve replacement. Dr. Varun Bhargav has been recognised with the Indian Medical association, Nagpur, Academy of medical sciences , Nagpur, Cardiological society of India, Vidarbha Chapter Nagpur, Cardiological society of India, Association of Physicians of India, and Society of Critical care Medicine.
He was the Principal investigator for Engage AF TIMI 48, configured the Single Arm Trial: Public Title of Study that included the study of drug used for the Reversal of Anticoagulant Effects of Dabigatran (Pradaxa), and was the Principal investigator for Study of reversal of the anticoagulant effect of dabigatran by intravenous administration of 5.0 gm of idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedure. He was also the principal investigator for a study to evaluate the effect of Dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction by Astrazeneca-Ongoing.
Hindi, English, Marathi